Table 4.
Characteristics of liver impairment according to the type of chemotherapy.
| Chemotherapy | Steatosis > 30% | Portal fibrosis ≥ 2 | Perisinusoidal fibrosis | Sinusoidal dilatation | NRH | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (n = 2) | (n = 13) | (n = 7) | (n = 18) | (n = 6) | |||||||||||
| Chemo+ | Chemo− | P | Chemo+ | Chemo− | P | Chemo+ | Chemo− | P | Chemo+ | Chemo− | P | Chemo+ | Chemo− | P | |
| LV5FU2 | 0/4 (0) | 1/17 (6) | 1 | 2/4 (50) | 3/17 (17.6) | 0.22 | 2/4 (50) | 0/17 (0) | 0.02 | 1/4 (25) | 4/17 (23.5) | 1 | 0/4 (0) | 1/17 (5.9) | 1 |
| Folfox | 1/19 (5.3) | 1/17 (6) | 1 | 5/18 (27.8) | 3/17 (17.6) | 0.69 | 4/19 (21.1) | 0/17 (0) | 0.10 | 10/19 (52.6) | 4/17 (23.5) | 0.07 | 4/19 (21) | 1/17 (5.9) | 0.34 |
| Xelox | 0/3 (0) | 1/17 (6) | 1 | 0/3 (0) | 3/17 (17.6) | 1 | 0/3 (0) | 0/17 (0) | 1 | 2/3 (66.6) | 4/17 (23.5) | 0.20 | 1/3 (33.3) | 1/17 (5.9) | 0.28 |
| Folfox and Xelox | 1/22 (4.5) | 1/17 (6) | 1 | 5/21 (24) | 3/17 (17.6) | 0.70 | 4/22 (18.2) | 0/17 (0) | 0.11 | 12/22 (54.5) | 4/17 (23.5) | 0.05 | 5/22 (22.7) | 1/17 (5.9) | 0.20 |
| Folfiri | 0/7 (0) | 1/17 (6) | 1 | 2/6 (33.3) | 3/17 (17.6) | 0.57 | 2/7 (28.6) | 0/17 (0) | 0.07 | 2/7 (28.6) | 4/17 (23.5) | 1 | 1/7 (14.3) | 1/17 (5.9) | 0.50 |